Tagged with GSK,

Brazil Alexei Kolchin, general manager of GSK Brazil, discusses adapting to Brazil, having previously held the equivalent role in Russia, the Brazilian affiliate’s contribution to GSK’s global growth, and its embrace of digitally disruptive technologies. Before being appointed GM of GSK in Brazil, you were the GM for GSK Russia, so…

Brazil Cesar Rengifo, senior vice president and area director Emerging Markets West at GSK, the fastest growing multinational company in both Brazil and Latin America, discusses the perfect match between GSK’s product portfolio and the region’s healthcare needs as well as the opportunities it entails for the company and Latin America’s…

Bulgaria Nikolaos Xydias, general manager at GSK Bulgaria, explains the commitment of GSK to cutting-edge medicines and vaccines targeting respiratory diseases and HIV and highlights the reasons why pharmaceutical multinationals should put Bulgaria on their business map. This is your first time as a country manager. How did you prepare yourself…

Colombia Adriana Forero, General Manager of GSK Colombia, speaks about their efforts to remain at the forefront of the healthcare industry, while keeping their focus on increasing access, innovation and focus on the patient in order to become a strategic partner for the Government and the Colombian healthcare system Ms. Forero,…

Indonesia Omar Luqmaan Harris, GM at GSK Indonesia, discusses the commitment of the Indonesian affiliate to the global organization’s mission, as well as their focus on being the best place to work, with the highest patient focus, and the best customer engagement. Mr. Harris, what have been your main areas of…

Philippines The Top 10 pharmaceutical companies in the Philippines by revenue. Unilab leads the way, followed by Pfizer and Abbot.

London Among the assorted pharma CEOs and KOLs gathered at the recent Financial Times Pharmaceutical and Biotechnology Conference in London, debate raged on the pros and cons of a pure play strategy, focusing on a few key therapeutic areas, compared to a more diversified approach. If the 1990s and early 2000s, were all…

Singapore In an exclusive interview with Richard Saynor at GSK, he outlines the growth of the CEP portfolio in emerging markets and highlights the opportunities and challenges in the region, as well as the strategic benefits of operating in Singapore.   Even though our key medicines have many generic competitors, their…

Pharma Daniel Breitenstein, VP and GM of GSK Switzerland, discusses the benefits of GSK’s three-part transaction with Novartis; the importance of respiratory diseases and vaccines for future success; and how the company has changed its business model by no longer paying for physicians to speak on their behalf, setting in process…

Pharma GSK Hungary’s Claire Roger discusses the value of ethical promotion both in improving transparency and benefiting all stakeholders. She further describes the strategic role and economic impact of GSK’s vaccine plant in Gödöllő and growth opportunities in HIV. Given that you’ve only recently arrived in May 2015, Claire, what priorities have been at the…

Pharma Hungary has long boasted a vibrant, skilled pharmaceutical industry that continues to attract the interest of local and multinational entities alike. This fact was highlighted today at the celebration of GlaxoSmithKline’s incorporation of new technologies and production units at its state-of-the-art Gödöllő Vaccine Facility on the outskirts of Budapest. While GSK’s dynamic…

Pharma In an exclusive interview at the eyeforpharma Barcelona Summit 2016, GSK’s Danie Du Plessis speaks out about patient-centricity and the growing role of medical affairs in the pharma industry. In your speech today, you mentioned that the concept of patient-centrality has not changed, but that expectations around it have; could you…